Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 79 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dynamic contrast-enhanced (DCE) MRI Clear all
Completed Phase 2 Interventional

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

NCT00352521
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 1, 2026, 9:22 PM EDT
Recruiting No phase listed Observational

Quantitative MRI Assessment of Breast Cancer Therapy Response

NCT05704062
View directory record Official record
Conditions
Breast Cancer
Interventions
Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Procedure
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
4
States / cities
Iowa City, Iowa • Royal Oak, Michigan • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 1, 2026, 9:22 PM EDT
Completed No phase listed Observational

Investigation of Diagnostic Improvement Gained Through Optimization of MR Methods for Breast Cancer Detection

NCT02411760
View directory record Official record
Conditions
Breast Neoplasms
Interventions
3 Tesla Magnetic Resonance Imaging
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Not applicable Interventional

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

NCT02359097
View directory record Official record
Conditions
Glioblastoma
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadoteridol, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Columbus, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

NCT01652196
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
aflibercept, oxaliplatin, leucovorin, fluorouracil, Correlative Studies, DCE MRI, f18FDG-PET, PET (positron emission tomography)
Biological · Drug · Other + 2 more
Lead sponsor
John Hays
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
6
States / cities
Ann Arbor, Michigan • Buffalo, New York • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 1, 2026, 9:22 PM EDT
Terminated No phase listed Observational

Metastatic Colorectal Cancer: Treatment Response With Dynamic Contrast MRI

NCT00820456
View directory record Official record
Conditions
Colorectal Neoplasm, Hepatic Neoplasm
Interventions
DCE-MRI
Other
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 1, 2026, 9:22 PM EDT
Completed No phase listed Observational

Quantitative Dynamic Contrast Enhanced Breast MRI

NCT00582764
View directory record Official record
Conditions
Breast Cancer
Interventions
perform dynamic contrast enhanced (DCE) MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

Doxil, Bevacizumab and Temsirolimus Trial

NCT00761644
View directory record Official record
Conditions
Advanced Cancer
Interventions
Doxil, Bevacizumab, Temsirolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Not applicable Interventional

Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors

NCT00598741
View directory record Official record
Conditions
Sarcoma, Bone Tumor
Interventions
DCE-MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

NCT01359982
View directory record Official record
Conditions
Malignant Solid Tumor, Lymphomas
Interventions
RRx-001
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
La Jolla, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Not applicable Interventional

Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection

NCT01575951
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
MRI-DCE
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Phase 2 Interventional

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

NCT02598596
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, Azathioprine
Biological · Drug
Lead sponsor
Ampel BioSolutions, LLC
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • Huntsville, Alabama • Wheaton, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Results available

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis

NCT00361634
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00662506
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
Cediranib Maleate, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Temozolomide
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)

NCT00330421
View directory record Official record
Conditions
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Osteosarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
sorafenib tosylate, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study, computed tomography, dynamic contrast-enhanced magnetic resonance imaging
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 1, 2026, 9:22 PM EDT
Active, not recruiting Early Phase 1 Interventional

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

NCT02744053
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Scintimammography, Technetium Tc-99m Sestamibi
Procedure · Other · Radiation + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
6
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 1, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional Results available

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

NCT00659126
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
Interventions
3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, High Field Strength Magnetic Resonance Imaging, Susceptibility Weighted Imaging
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Early Phase 1 Interventional

Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

NCT01221506
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pazopanib, DCE-MRI and Quantitative Doppler Ultrasound
Drug · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 1, 2026, 9:22 PM EDT
Completed No phase listed Observational

Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy

NCT02496260
View directory record Official record
Conditions
Breast Cancer
Interventions
Research Cardiac MRI, Biomarkers
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 1, 2026, 9:22 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

NCT02623972
View directory record Official record
Conditions
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
Eribulin, Adriamycin, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Early Phase 1 Interventional

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

NCT05250895
View directory record Official record
Conditions
BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions
18F-Fluoromisonidazole, Biopsy, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 1, 2026, 9:22 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

NCT04341129
View directory record Official record
Conditions
Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer
Interventions
Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 1, 2026, 9:22 PM EDT
Recruiting Phase 2 Interventional

Advanced Imaging for Pulmonary Fibrosis

NCT06532071
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
[68Ga]CBP8, Gadoterate Meglumine
Drug
Lead sponsor
Peter Caravan
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 1, 2026, 9:22 PM EDT
Completed No phase listed Observational

Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion

NCT02376127
View directory record Official record
Conditions
Solid Cancer, Metastatic Spinal Lesions
Interventions
Dynamic contrast enhancement MRI
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 1, 2026, 9:22 PM EDT